Brief: Lantern Pharma Completes FDA Type C Meeting On Pediatric CNS Cancer Trial
03/09/2025 14:53
Sept 3 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA ANNOUNCES COMPLETION OF TYPE C MEETING WITH FDA, PROVIDING CLARITY ON REGULATORY PATHWAY FOR PEDIATRIC CNS CANCER TRIAL LANTERN PHARMA INC - FDA CONFIRMS POTENTIAL INCORPORATION OF SPIRONOLACTONE AS COMBINATION AGENT IN TRIAL LANTERN PHARMA INC - PLANS IND AMENDMENT SUBMISSION & TRIAL INITIATION FOR PEDIATRIC CNS CANCER TRIAL IN Q1 2026 Source text: ID:nBwbG7HD1a Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments